SAN DIEGO and PENNINGTON, N.J., July
17, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer
immunotherapies, today announced that Sharron Gargosky, PhD,
Chief Clinical and Regulatory Officer, presented a clinical update
of the Company's intratumoral therapy, ImmunoPulse™ tavokinogene
telseplasmid (TAVO), as well as an overview of the ongoing and
anticipated clinical programs involving TAVO in triple-negative
breast cancer (TNBC). The presentation, titled "Intra-tumoral
delivery of tavokinogene telseplasmid (pIL-12) by electroporation:
immunomodulation in melanoma and triple negative breast
cancer," took place at the 3rd Global Insight Conference
on Breast Cancer in Valencia,
Spain.
"We were grateful for the opportunity to present at the 3rd
Global Insight Conference on Breast Cancer and share progress from
our TAVO clinical programs with the clinicians, biotechnology
executives, and industry opinion leaders in attendance. Metastatic
TNBC is a heterogeneous cancer with a poor prognosis where less
than five percent of pre-treated patients achieve an objective
response to PD-1/PD-L1 checkpoint treatments," said Dr. Gargosky.
"The marked synergy shown in these patients strongly suggest that
IL-12 may have primed the tumor microenvironment, impacting the
clinical result. The combination of TAVO and checkpoint inhibition
represents a highly promising new therapeutic approach for TNBC and
warrants a formal evaluation given the extremely low response rate
in women who have failed multiple prior therapies."
The ongoing Phase 1 TNBC study, OMS-140 (NCT02531425), is
designed to determine whether TAVO as a single cycle of monotherapy
can elicit a pro-inflammatory molecular and histological signature
in treated as well untreated tumors. The study has reached its
target enrollment of 10 patients. Several of these patients
were subsequently treated with an anti-PD-1 checkpoint inhibitor
treatment(s) as their next therapy. As previously reported at the
American Association for Cancer Research (AACR) Annual Meeting,
immunological signals were observed on an individual patient basis,
and clinically meaningful objective tumor responses have been
observed in both TAVO treated and untreated lesions following the
anti-PD-1 checkpoint inhibitor treatment. A detailed case
study of one such patient, along with information regarding
clinical observations and safety data, were presented at this
conference.
Following these observations, the Company entered a clinical
collaboration with Merck to evaluate the combination of TAVO with
Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 2
clinical trial, KEYNOTE-890 (NCT03567720). KEYNOTE-890 is a study
of TAVO in combination with KEYTRUDA® in TNBC patients with
inoperable locally advanced or metastatic TNBC who have progressed
on more than one line of prior therapy. Patients will be treated
with the combination of TAVO with pembrolizumab. The proposed
primary endpoint is to assess efficacy as measured by objective
response rate (ORR) by independent central review (ICR) based on
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
KEYNOTE-890 is expected to initiate in the third quarter of
2018.
Dr. Gargosky's update is available on the OncoSec website,
www.oncosec.com.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "TAVO"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to TAVO, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
jmccargo@tiberend.com
dschemelia@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-presents-update-from-triple-negative-breast-cancer-program-at-3rd-global-insight-conference-on-breast-cancer-300681890.html
SOURCE OncoSec Medical Incorporated